Ascendis Pharma (ASND) – Press Releases
-
VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China
-
Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024
-
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
-
Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024
-
Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism
-
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
-
Er-Kim Announces Exclusive Distribution Agreement with Ascendis Pharma A/S to Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe and Turkey
-
Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries
-
Ascendis Pharma Introduces Vision 2030
-
Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries
-
Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
-
Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week
-
TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency
-
FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism
-
Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan
-
Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the Treatment of Adults with Chronic Hypoparathyroidism
-
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in ACcomplisH China Phase 2 Trial
-
Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDA
-
Ascendis Pharma Reports Third Quarter 2023 Financial Results
-
Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission
-
Ascendis Presents Updated and New TransCon™ IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023
-
Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023
-
ASCENDANT ANNOUNCES APPOINTMENT OF MR. VAL COETZEE AS DIRECTOR OF PROCESS ENGINEERING
-
Ascendis Presents TransCon™ PTH Data at the American Thyroid Association Annual Meeting
-
Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency
-
Ascendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone Deficiency
-
Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism
-
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
-
Ascendis Pharma Reports Second Quarter 2023 Financial Results
-
New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism
-
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
-
ASCENDANT RESOURCES ENTERS TENDER PHASE FOR MANDATED LEAD ARRANGER FOR ITS EXPORT CREDIT AGENCY SUPPORTED PROJECT FINANCING AT ITS LAGOA SALGADA PROJECT IN PORTUGAL
-
Ascendis Pharma A/S Announces Three Upcoming Investor Presentations
-
Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders
-
Ascendis Pharma to Report Second Quarter 2023 Financial Results and Provide Business Update on September 5, 2023
-
ASCENDANT RESOURCES EARNS 80% INTEREST IN THE LAGOA SALGADA PROJECT IN PORTUGAL AND FILES FEASIBILITY STUDY
-
ASCENDANT RESOURCES ANNOUNCES POST-TAX NPV8 OF US$147 MILLION AND 39% IRR FROM INITIAL FEASIBILITY STUDY AT ITS LAGOA SALGADA PROJECT IN PORTUGAL
-
ASCENDANT RESOURCES ANNOUNCES DATE OF ANNUAL SHAREHOLDERS' MEETING
-
ASCENDANT ANNOUNCES POTENTIAL EXPORT CREDIT AGENCY SUPPORT FOR PROJECT FINANCE AT ITS LAGOA SALGADA PROJECT IN PORTUGAL
-
Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating Zai Lab, Hayward, Ascendis, and Alvotech and Encourages Investors to Contact the Firm
-
ASCENDANT PROVIDES UPDATE FOR ITS LAGOA SALGADA PROJECT IN PORTUGAL
-
Bragar Eagel & Squire, P.C. Is Investigating C3.ai, Ascendis, Alvotech, and Shift4 and Encourages Investors to Contact the Firm
-
One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023
-
Ascendis Pharma Showcases Its Latest Endocrinology Programs, Data, and Research at ENDO 2023
-
Ascendis Pharma to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
-
Ascendis Pharma Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany
-
Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates
-
Juha Punnonen, M.D., Ph.D. Joins Hinge Bio as Chief Development Officer
Back to ASND Stock Lookup
